Third Phase III study (AD Up) of upadacitinib plus topical corticosteroids (TCS) reports improved skin and itch symptoms in atopic dermatitis patients

Study found more patients on 15 mg and 30 mg doses of upadacitinib plus TCS showed improvement in skin clearance vs. placebo plus TCS at week 16 (65 and 77 % achieved EASI 75, respectively, vs 26% placebo plus TCS (p<0.001).


Biospace Inc.